June 30, 2017
J Diagn Treat Oral Maxillofac Pathol 2017;1:77−88.
Under a Creative Commons license
Hatab N, Patel T, Bakkour A. The efficiency of rhBMP-7 in oral and maxillofacial bone defects: a systematic review. J Diagn Treat Oral Maxillofac Pathol 2017;1(2):77−88.
Background: Bone morphogenic protein-7 (BMP-7) is a molecule that has been clinically trialed and tested for use in regeneration of bone defects and its ability to induce bone formation by induction of gene
expression. Recombinant human BMP-7 (rhBMP-7) has surgical uses and is marketed under the brand name OP-1 (Olympus Biotech Corporation). With the ever expanding discipline of oral surgery and the need for regenerative therapy for bone defects in the oral and maxillofacial region, this study was undertaken to compare the outcomes of different methods of use of BMP-7.
Methods: The authors retrieved English publications on relevant studies from PubMed, ScienceDirect and Google Scholar from 2000 to 2016. In vitro and in vivo studies were included. The main outcomes
were increased expression of osteogenic genes and radiographic bone fill.
Results: In total, 676 human studies in the literature were identified but only four were ultimately feasible. The results showed a significant effect of rhBMP-7 both in-vitro and in-vivo. In all the studies used a systematic review was used to compare the outcomes of using rhBMP-7. The in vivo samples showed significant radiographic fill and efficient bone deposition. In vitro studies showed increased
expression of OCN and ALP biomarkers.
Conclusions: rhBMP-7 is an effective tool that can be used to improve and speed up regenerative therapy of bone defects. However further human studies are needed to enhance and develop the use of this molecule in vitro.